ArticleFrontiers in medicine2026
Renal outcomes and predictive value of dyslipidemia in patients with IgA nephropathy: a retrospective cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dyslipidemia is common in chronic kidney disease (CKD), including immunoglobulin A (IgA) nephropathy (IgAN), and may be associated with renal prognosis; however, the value of dyslipidemia in IgAN remains insufficiently assessed. The objective of our study was to investigate clinicopathological characteristics and renal outcomes in IgAN patients with dyslipidemia and to evaluate the prognostic value of lipid abnormalities. Methods: This cohort study included 458 primary IgAN patients for a retrospective analysis. The clinicopathological features and renal outcomes were recorded. In univariate and multivariate models, the associations between dyslipidemia and renal outcomes, as well as dyslipidemia-associated pathological features, were analyzed. Results: Patients with dyslipidemia-defined as a total cholesterol of ≥5.2 mmol/L, triglycerides of ≥1.7 mmol/L, or low-density lipoprotein cholesterol [LDL-C] of ≥3.4 mmol/L-exhibited elevated complement levels and worse clinical characteristics with regard to blood pressure, proteinuria, kidney function, and glomerulosclerosis; tubular atrophy/interstitial fibrosis (T1-2), crescents, and vascular lesions were more common. A multivariate logistic regression revealed that T1-2 and arterial intimal fibrosis were significantly associated with dyslipidemia. After a mean follow-up of 54.7 months, dyslipidemia ( Conclusion: IgAN patients with dyslipidemia exhibited more severe clinicopathological features. Tubular atrophy/interstitial fibrosis and arteriosclerosis/arteriolosclerosis were closely associated with dyslipidemia. Dyslipidemia not only indicates adverse renal outcomes but also serves as an independent prognostic predictor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.